Standout Papers

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That ... 2001 2026 2009 2017 8.3k
  1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 (2001)
    Dennis J. Slamon, Brian Leyland‐Jones et al. New England Journal of Medicine
  2. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer (2012)
    Sunil Verma, David Miles et al. New England Journal of Medicine
  3. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2003)
    Masahiro Fukuoka, Seiji Yano et al. Journal of Clinical Oncology
  4. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (2011)
    José Baselga, Javier Cortés et al. New England Journal of Medicine
  5. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma (2011)
    Aleksandar D. Kostic, Dirk Gevers et al. Genome Research
  6. The EGF receptor family as targets for cancer therapy (2000)
    John Mendelsohn, José Baselga Oncogene
  7. Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer (2003)
    John Mendelsohn, José Baselga Journal of Clinical Oncology
  8. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009)
    José Baselga, Sandra M. Swain Nature reviews. Cancer
  9. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (2017)
    Gϋnter von Minckwitz, Marion Procter et al. New England Journal of Medicine
  10. Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab (2007)
    Shirin Khambata‐Ford, Christopher R. Garrett et al. Journal of Clinical Oncology
  11. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort (2010)
    Luca Gianni, W. Eiermann et al. The Lancet
  12. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. (1998)
    José Baselga, Larry Norton et al. PubMed
  13. AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity (2011)
    Sarat Chandarlapaty, Ayana Sawai et al. Cancer Cell
  14. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer (2010)
    Kimberly Blackwell, Harold J. Burstein et al. Journal of Clinical Oncology
  15. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types (2002)
    José Baselga, Danny Rischin et al. Journal of Clinical Oncology
  16. Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer (2007)
    Maurizio Scaltriti, Federico Rojo et al. JNCI Journal of the National Cancer Institute
  17. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization (2002)
    Incheol Shin, F. Michael Yakes et al. Nature Medicine
  18. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. (2001)
    Miguel Ángel Molina‐Vila, Jordi Codony‐Servat et al. PubMed
  19. Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin (2000)
    José Baselga, David G. Pfister et al. Journal of Clinical Oncology
  20. Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer (2005)
    José Baselga, Carlos L. Arteaga Journal of Clinical Oncology
  21. Epidermal Growth Factor Receptor Targeting in Cancer (2006)
    John Mendelsohn, José Baselga Seminars in Oncology
  22. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials (2005)
    Daphne W. Bell, Thomas J. Lynch et al. Journal of Clinical Oncology
  23. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. (2002)
    John W. Park, Keelung Hong et al. PubMed
  24. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer (2016)
    María Teresa Herrera-Abreu, Marta Palafox et al. Cancer Research

Immediate Impact

25 from Science/Nature 172 standout
Sub-graph 1 of 15

Citing Papers

CDK4 and CDK6 kinases: From basic science to cancer therapy
2022 StandoutScience
Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer
2022 StandoutNature
23 intermediate papers

Works of José Baselga being referenced

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
2016 Standout
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma
2011 Standout
and 5 more

Author Peers

Author Last Decade Papers Cites
José Baselga 34173 17049 13302 270 48.4k
José Baselga 25287 19503 13824 482 45.7k
Dennis J. Slamon 44305 23233 15373 412 64.3k
Gary M. Clark 27959 13822 10472 265 43.7k
Louis Fehrenbacher 24845 8769 10026 156 35.2k
Janet Dancey 19412 8425 15054 202 37.3k
Carlos L. Arteaga 18114 19578 7120 429 34.0k
Richard Kaplan 22048 7159 19835 171 45.0k
Bruce E. Johnson 29340 20418 28871 411 49.7k
Seock‐Ah Im 23147 7039 13475 652 31.7k
Howard A. Burris 25010 12786 10502 737 37.4k

All Works

Loading papers...

Rankless by CCL
2026